Cargando…
Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma
Camrelizumab (SHR-1210) is a humanized IgG4 monoclonal anti-programmed cell death protein 1 (PD-1) antibody that has been shown to inhibit the binding of PD-1 to PD-L1, thereby blocking the immune escape of various types of cancer, including lung squamous cell carcinoma (LSCC). Reactive cutaneous ca...
Autores principales: | Ma, Rong, Wang, Jia-Lin, Wang, Yan-Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607856/ https://www.ncbi.nlm.nih.gov/pubmed/36289520 http://dx.doi.org/10.1186/s40164-022-00336-4 |
Ejemplares similares
-
Emerging Treatments for Reactive Cutaneous Capillary Endothelial Proliferation
por: Liu, Yi, et al.
Publicado: (2023) -
Thalidomide for prevention of camrelizumab‐induced reactive cutaneous capillary endothelial proliferation
por: Song, Geng, et al.
Publicado: (2022) -
Acute Paronychia and Reactive Capillary Proliferation in a Patient on Erlotinib
por: Kaur, Ishmeet, et al.
Publicado: (2020) -
Reactive Cutaneous Capillary Endothelial Proliferation Caused by Camrelizumab: Sixteen Case Reports
por: Hui-Mei, Pang, et al.
Publicado: (2023) -
Reactive cutaneous capillary endothelial proliferation predicted the efficacy of camrelizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma
por: Ding, Qi, et al.
Publicado: (2023)